Noortje van Herwaarden

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

Noortje van Herwaarden, Aatke van der Maas, M.J.M. Minten et al. · BMJ · 2015 · 178 citations · Full text

Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Wietske Kievit, Noortje van Herwaarden, F.H.J. van den Hoogen et al. · Annals of the Rheumatic Diseases · 2016 · 49 citations

Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial

Chantal A M Bouman, Noortje van Herwaarden, F.H.J. van den Hoogen et al. · Annals of the Rheumatic Diseases · 2017 · 47 citations

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study

Alfons A den Broeder, Noortje van Herwaarden, Aatke van der Maas et al. · BMC Musculoskeletal Disorders · 2013 · 40 citations · Full text

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis

Lieke Tweehuysen, Nathan den Broeder, Noortje van Herwaarden et al. · RMD Open · 2018 · 39 citations · Full text